These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27669306)

  • 21. [Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
    Busch CJ; Laban S; Knecht R; Hoffmann TK
    HNO; 2016 Oct; 64(10):708-16. PubMed ID: 27604282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma.
    Wang HC; Chan LP; Cho SF
    Front Oncol; 2019; 9():1084. PubMed ID: 31681613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy.
    Shibata H; Saito S; Uppaluri R
    Front Oncol; 2021; 11():727433. PubMed ID: 34552878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Vaccination in Head and Neck Squamous Cell Carcinoma-A Review.
    Devaraja K; Aggarwal S; Singh M
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for head and neck cancer: the future of treatment?
    Xie X; O'Neill W; Pan Q
    Expert Opin Biol Ther; 2017 Jun; 17(6):701-708. PubMed ID: 28368668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma.
    Veigas F; Mahmoud YD; Merlo J; Rinflerch A; Rabinovich GA; Girotti MR
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33804419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
    Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
    Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
    Su YY; Chien CY; Luo SD; Huang TL; Lin WC; Fang FM; Chiu TJ; Chen YH; Lai CC; Hsu CM; Li SH
    World J Surg Oncol; 2016 Mar; 14():86. PubMed ID: 27001663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCG immune activation reduces growth and angiogenesis in an in vitro model of head and neck squamous cell carcinoma.
    Sánchez-Rodríguez C; Cruces KP; Riestra Ayora J; Martín-Sanz E; Sanz-Fernández R
    Vaccine; 2017 Nov; 35(47):6395-6403. PubMed ID: 29029943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
    Bowles DW; McDermott JD; Jimeno A
    Future Oncol; 2014 May; 10(6):1065-80. PubMed ID: 24941990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Sacco AG; Cohen EE
    J Clin Oncol; 2015 Oct; 33(29):3305-13. PubMed ID: 26351341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for Head and Neck Cancer.
    Sim F; Leidner R; Bell RB
    Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Jacob LA; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2016; 53(4):471-477. PubMed ID: 28485332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.
    Haque S; Yellu M; Randhawa J; Hashemi-Sadraei N
    Drug Des Devel Ther; 2017; 11():2537-2549. PubMed ID: 28919706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B; Young RJ; Rischin D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy for Head and Neck Cancer.
    Sim F; Leidner R; Bell RB
    Oral Maxillofac Surg Clin North Am; 2019 Feb; 31(1):85-100. PubMed ID: 30449528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma.
    Cooper T; Biron VL; Fast D; Tam R; Carey T; Shmulevitz M; Seikaly H
    J Otolaryngol Head Neck Surg; 2015 Feb; 44(1):8. PubMed ID: 25890191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.